Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Avista Pharma Solutions, Inc. dba Cambrex
EIR
•Avista Pharma Solutions, Inc. dba Cambrex•November 9, 2018

Avista Pharma Solutions, Inc. dba Cambrex – FDA EIR, Nov 9, 2018

Record Details

Avista Pharma Solutions in Longmont, CO, underwent an initial FDA current Good Manufacturing Practice (CGMP) inspection from November 7-9, 2018, focusing on its control testing laboratory for human and animal drugs. The main violation identified was the Quality Unit's failure to review and approve all associated records related to the testing of Active Pharmaceutical Ingredient (API) drug products. Specifically, computerized software audit trails for GMP testing of treprostinil diolamine API and riluzole API were not being reviewed by Quality Assurance or its designee. The company's corporate procedure for technical review of laboratory data also lacked provisions for computerized audit trail review, which are crucial for ensuring data integrity by documenting data creation, modification, and deletion. This observation cited a deficiency in adhering to 21 CFR 211.22(a), related to Quality Control Unit responsibilities. In response, management committed to providing a written reply to the FDA within 15 business days. They also committed to revising procedures to include audit trail reviews and had already conducted a retrospective review of the affected audit trails. The company is actively pursuing a Data Integrity Remediation Project Plan to address audit trail capabilities and implement necessary corrective actions across all relevant computerized systems.

Company
Avista Pharma Solutions, Inc. dba Cambrex
Inspection date
November 9, 2018
Product type
drugs
Office
Denver District Office
People
  • Kenneth A. Domagalski (recipient)
  • Cathy Butler (company_representative)
  • Erika V. Butler (Compliance Officer / Investigator)
  • Kelly Kaufman (company_representative)
  • TJ Harper (company_representative)
View Company Profile

ID · 167b58b2-f867-4129-9f5c-c4d4237e5b90

Violation Codes4
21 CFR 820.19821 CFR 21121 CFR 21021 CFR 211.22(a)

Full citation text and observation details available on the Dashboard.

Other documents for Avista Pharma Solutions, Inc. dba Cambrex
  • 483 - 2024-05-03May 3, 2024

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Avista Pharma Solutions, Inc. dba Cambrex
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.